Procos

Executive Summary

Procos S.p.A. is an Italian Contract Development and Manufacturing Organization (CDMO) wholly owned by Japan's CBC Co. Ltd Group. Founded in 1980, the company specializes in the development, scale-up, and production of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. Its large, multi-purpose cGMP manufacturing facility in Cameri, Italy, supports both custom synthesis for innovator companies and generic API production. Procos serves a global client base, positioning itself as a reliable partner in the pharmaceutical supply chain. As a private subsidiary, Procos benefits from the financial stability and strategic resources of its parent group while maintaining operational autonomy. The CDMO market continues to grow driven by pharmaceutical outsourcing trends, and Procos is well-positioned to capture demand for high-quality API manufacturing. With increasing regulatory requirements and the need for cost-effective production, the company's expertise in complex synthesis and cGMP compliance provides a competitive edge. While specific financials are not publicly disclosed, the company's sustained operation for over four decades indicates resilience and steady performance. Future growth will likely hinge on capacity expansions and new client agreements.

Upcoming Catalysts (preview)

• Q3 2026Capacity expansion at Cameri facility70% success
• Q3 2026New long-term supply agreement with a top-20 pharma company50% success
• Q3 2026Regulatory approval for a high-value generic API60% success